Back to news

VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting

Globe Newswire•16/11/2026•08:05 ET
0

Key Highlights

  • ➤10 discontinued drug candidates flagged by NAMkind Liver after animal safety clearance
  • ➤17-day repeated dosing tracked four liver injury endpoints across clinical candidates
  • ➤Five CDK inhibitors showed diverse regional and endpoint-specific intestinal toxicity profiles
  • ➤Vedotin-linked ADCs caused severe barrier breakdown in differentiated colon epithelium
  • ➤VivoSim presented liver and intestine studies at 2026 ACT Annual Meeting

Expert Statements

Dr. Amar A. Sethi, Chief Scientific Officer at VivoSim Labs

“Traditional single-endpoint assays and animal models frequently fail to capture delayed or human-specific metabolic liabilities. By applying a rigorous multiparametric approach in NAMkind™ Liver, we are able to look beyond basic cell viability and map out the exact convergence of various tissue stresses (functional, oxidative, and metabolic). This gives sponsors actionable mechanistic insight into liver toxicity risk margins long before clinical trials begin.”

Keith Murphy, Executive Chairman at VivoSim Labs

“Gastrointestinal toxicity is a major hurdle in oncology and targeted therapeutics, yet conventional systems struggle to differentiate regional and cellular-state sensitivities. Our latest intestinal data show that NAMKind Intestine regional tissue architecture with multiparametric readouts provides close correlation with known clinical outcomes. This system provides biopharma developers with an unprecedented lens to evaluate epithelial barrier integrity, optimize lead candidates, and align with modern regulatory frameworks like the FDA Modernization Act 2.0.”

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc., (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader and pioneer in next generation human-relevant New Approach Methodologies (NAMs) 3d human cellular models for preclinical safety and translational efficacy, announced today that its scientific team is presenting two landmark studies at the 2026 American College of Toxicology (ACT) Annual Meeting, taking place November 15–18 in San Antonio, Texas.

The presentations underscore the transformative power of VivoSim’s multiparametric approach across its proprietary NAMkind™ Liver and NAMkind™ Intestine platforms. Instead of measuring solely cell death, VivoSim sets a new standard by integrating multiple complementary endpoints with extended repeat-dose experimentation.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in